ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings ANX007 protected key retinal structures important for vision: significant reduction of photoreceptor loss and meaningful slowing of lesion growth measured by retinal pigment epithelium (RPE) loss in the fovea C1q blockade protected photoreceptor synapses and preserved retinal function in preclinical model, supporting the mechanistic understanding of ANX007 in preserving synap ...